A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies Meeting Abstract
| Authors: | O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; Macgregor-Cortelli, B.; Pappanicolu, J.; Zelentz, A.; Sirotnak, F.; Fleischer, M.; Mould, D.; Saunders, M.; Horwitz, S. |
| Abstract Title: | A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies |
| Meeting Title: | AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics |
| Journal Title: | Molecular Cancer Therapeutics |
| Volume: | 6 |
| Issue: | 12 |
| Meeting Dates: | 2007 Oct 22-26 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 1535-7163 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2007-12-01 |
| Start Page: | 3554S |
| Language: | English |
| ACCESSION: | WOS:000251969000670 |
| PROVIDER: | wos |
| Notes: | --- - Meeting Abstract: C85 - Part 2 - "Source: Wos" |
